Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| Lumentum Holdings | Digital Realty Trust | Pfizer | |
|---|---|---|---|
| Moat rating | narrow FY2025 10-K (filed 2025-08-19) grounds a narrow rating: on one side ~1,020 U.S. and ~1,100 foreign patents with expirations through 2045 plus vertically integrated wafer fabs (US, UK, Japan, Thailand) behind its laser chips and photonic ICs; on the other, Item 1A states optical communications products 'have increasingly become subject to commoditization' with 'predominantly Asia-based competitors' intensifying pricing pressure and a historical 'continued decline of average selling prices' expected to continue. | narrow The FY2025 10-K's own competitive record cuts both ways. Item 1 says a "high-quality, highly interconnected global portfolio such as ours could not be easily replicated today on a cost-competitive basis," yet Item 1A concedes that competitors have "significantly greater financial, marketing and other resources and more ready access to capital" and that as rivals keep developing space, "rental rates may be reduced or we may face delays in leasing." A durable advantage that its own filing says new supply can price against is bounded, not unassailable. | eroding The FY2025 10-K publishes the expiry schedule of its own protection. The Patents table dates the basic U.S. product patent on Eliquis ($7,961 million of 2025 revenue) to 2027, the Prevnar family's Prevnar 13 ($6,494 million for the family) to 2026, the Vyndaqel family ($6,380 million) to 2026 with a 2028 extension only pending, Ibrance ($4,122 million) to 2027, Xtandi ($2,194 million) to 2027 and Xeljanz ($1,087 million) to 2026 - against Total revenues of $62,579 million. The filing then states it anticipates 'a significant reduction of revenue from patent-based or regulatory exclusivity expiries in 2026 through 2030 as several of our in-line products experience these expirations, with the rate of the reduction of revenues from patent-based or regulatory exclusivity expiries expected to significantly accelerate over the next few years', and puts the 2026 instalment at $1.5 billion. A protection whose end dates the issuer tabulates product by product, and whose revenue effect it forecasts as accelerating, is being consumed on a clock it has already disclosed. |
| Moat type | intangibles ip Per the FY2025 10-K, the moat rests on intangibles/IP and process know-how: patent portfolio (~1,020 U.S. / ~1,100 foreign, ~780 pending), InP laser and photonic-integrated-circuit technology (Oclaro, NeoPhotonics acquisitions), coherent DSP/ASIC lines (IPG telecom transmission acquisition), and its own wafer fabrication, assembly and test facilities — the company states it does not broadly license its IP absent adequate consideration or cross-licenses. | network effects Item 1 attributes the hard-to-replicate part of the portfolio to connectivity rather than to real estate: "the network density, interconnection infrastructure and connectivity-centric customers in certain of our data centers have led to the organic formation of densely connected data communities that are difficult for competitors to replicate." That community sits on over 232,000 cross connects in over 55 metros, so each network and cloud that lands makes the same building worth more to the next tenant. | intangibles ip The filing locates the protection in the patent estate, not anywhere else. The Patents and Other Intellectual Property Rights section tabulates 'the patent rights we consider most significant in relation to our business as a whole, together with the year in which the basic product patent expires', and states that once protection is lost 'we typically lose market exclusivity on these products, and generic and biosimilar pharmaceutical manufacturers generally produce identical or highly similar products and sell them for a lower price.' The Competition section names patents as the thing rivals attack: 'several of our competitors operate without large R&D expenses and make a regular practice of challenging our product patents before their expiration', and 'Generic pharmaceutical manufacturers pose one of the biggest competitive challenges to our branded small molecule products because they can market a competing version of our product after the expiration or loss of our patent protection.' No network, switching cost or cost-curve advantage is claimed anywhere in the section. |
| Leadership | co leader Mixed by layer: the FY2025 10-K self-describes Lumentum as 'a leading provider of optical and photonic products... recognized as an industry leader based on revenue and market share' (company's own characterization), while LightCounting's May 2026 optical vendor landscape places Lumentum near the bottom of its transceiver-only Top 10 — noting the list 'accounts for sales of optical transceivers only, excluding all other products, which explains lower rankings of Coherent and Lumentum' and that 'Neither CIG nor Lumentum plan to stay at the bottom of the list for much longer.' Co-leader in optical components/chips; follower in merchant transceiver modules behind Innolight and Eoptolink. | co leader Item 1 claims the title of "the largest global provider of cloud- and carrier-neutral data center, colocation and interconnection solutions," but the Competition section names Equinix and NTT as operators of properties "similar to ours in some of the same metropolitan areas," plus Global Switch and regional operators abroad — a shared top tier on the company's own telling, not a solitary one. | co leader The 2026 Pharma 50 (Drug Discovery & Development, published 31 March 2026, ranking pharmaceutical revenue only) places Pfizer third at $62.58 billion of FY2025 revenue inside a five-company band that runs from Johnson & Johnson's Innovative Medicine at $60.40 billion to Eli Lilly's $65.18 billion, with Merck & Co. at $65.01 billion and AbbVie at $61.16 billion in between - scale-equal to its nearest peers rather than ahead of them. The same piece attributes the top slot to Lilly's tirzepatide franchise, which it puts at $36.5 billion combined and says passed Keytruda as the world's best-selling drug; Pfizer's 10-K names no comparable single franchise, discloses no market-share position for any product, and concedes in Item 1A that 'some of our competitors may have competitive, technical or other advantages over us' and that it faces 'an increasing number of potential competitors worldwide, including from China, that have expanded R&D capabilities.' |
| Pricing power | moderate The May 5, 2026 Q3 FY2026 earnings release shows current pricing traction — CEO cites 'operational rigor, pricing discipline, and product mix' behind a 540 bps sequential non-GAAP gross-margin gain to 47.9% — but the FY2025 10-K states pricing pressures 'have led to a continued decline of average selling prices across our business and we expect that these historical trends will continue,' so power is cyclical/mix-driven rather than structural. | strong FY2025 renewals signed re-priced upward in every bucket — +27.0% on greater-than-1 MW space ($146 to $186 per square foot), +4.6% on 0-1 MW ($268 to $280) and +43.0% on other ($49 to $71) — and MD&A expects average aggregate rental rates on 2026 renewals to be positive against the rates currently paid for the same space "on a GAAP basis and on a cash basis." On costs, the filing says utilities expense "is our largest expense category" and that "the vast majority of the expense is passed directly through to our customers," which it credits with significantly mitigating exposure to power-cost increases rather than removing it. The cap: Item 1A warns competitor development could still force rates down. | weak Price is the lever the filing shows moving against it. CMS selected Eliquis - which the 10-K says 'accounted for 13% of Total revenues in 2025' - for the Medicare Drug Price Negotiation Program, and 'its government-set Maximum Fair Price became effective January 1, 2026', with Ibrance and Xtandi following in 2027 and Xeljanz in 2028. In September 2025 Pfizer 'voluntarily agreed' with the U.S. administration to make certain U.S. prices 'more comparable to those in other developed countries' and to sell through the TrumpRx.gov platform 'at significant discounts to current retail prices'. Gross-to-net product revenue deductions rose to $36,374 million in 2025 from $30,048 million in 2023 while Total revenues fell to $62,579 million, and the IRA Medicare Part D Redesign alone 'negatively impacted our 2025 revenues by approximately $1 billion'. Lower U.S. net price is named as a drag on Vyndaqel, Ibrance, Xeljanz, Nurtec ODT and Lorbrena; every 2025 growth line the filing explains is attributed to demand, patient share or launch uptake, none to price. Cost of sales at 25.7% of revenues shows the manufactured margin is intact - what is not intact is the ability to set the price. |
| Summary | Lumentum is an optical and photonics supplier whose FY2025 10-K describes two segments: Cloud & Networking ($1,410.8M of $1,645.0M FY2025 revenue) spanning datacom transceivers (Cloud Light), laser chips/EML transmitters, photonic ICs, co-packaged optics, optical circuit switches, and telecom transport (ROADMs, tunable and coherent components, pump lasers); and Industrial Tech ($234.2M) in fiber/ultrafast/diode lasers and 3D-sensing VCSELs. AI datacenter demand has inflected the business: the May 5, 2026 Q3 FY2026 release reports record revenue of $808.4M, up 90.1% YoY, with non-GAAP gross margin of 47.9% and the CEO crediting laser-chip strength, 'scale-across' components (pump lasers, narrow-linewidth laser assemblies), and pricing discipline, with co-packaged optics and optical circuit switches named as the next growth drivers. The moat is real but narrow: differentiation lives in photonic chip IP and vertical fab integration, while the transceiver-module layer commoditizes — LightCounting's May 2026 vendor landscape ranks Lumentum near the bottom of its transceiver-only Top 10 behind Innolight ($5.3B 2025 revenue) and Eoptolink, and Cignal AI (April 21, 2026) sizes 2025 datacom optical component revenue above $19B, up more than 70%, a market where scale rivals are growing as fast or faster. Customer concentration (top customers 16.0% and 15.4% of FY2025 revenue) and the 10-K's ASP-decline language cap the rating below wide. | Digital Realty rents space, power and connectivity rather than compute: at 2025 year-end its portfolio held 310 data centers and roughly 57.6 million rentable square feet across more than 55 metros in over 30 countries, about 84.7% leased, serving more than 5,000 customers. Two different businesses sit inside that footprint. The greater-than-1 MW wholesale side is a capital-and-power race — 769 MW of projects underway with 64% pre-leased, and land that "could accommodate over 3,500 megawatts of additional data center capacity" — where the 10-K names Equinix, NTT, Global Switch and "various private operators" as rivals and warns that added supply can push rents down. The colocation and interconnection side is the defended half: over 232,000 cross connects and the "densely connected data communities" Item 1 says competitors cannot easily replicate, reinforced by contracts the filing describes as generally running 5-10+ years on large deployments and by improvements "installed at our customers' expense." FY2025 leasing supports that read — renewals signed re-priced +27.0% on greater-than-1 MW space and +4.6% on 0-1 MW — while customer concentration is the offsetting exposure, with the largest customer at roughly 11.7% of annualized recurring revenue. | Two clocks run in opposite directions inside the same company. The revenue base is near-dated: Eliquis, the Prevnar family, the Vyndaqel family, Ibrance, Xtandi and Xeljanz all carry U.S. basic product patents expiring 2026 or 2027 in the 10-K's own table, and the filing warns the resulting revenue loss will 'significantly accelerate over the next few years'. The replacement book is later-dated - Padcev and Lorbrena to 2033, Nurtec ODT and Litfulo to 2034, Prevnar 20 to 2035, Abrysvo, Cibinqo and Elrexfio to 2036, Comirnaty and Paxlovid to 2041 - but in 2025 it was still much smaller, and the two products with the longest patent runway are the two the filing says are shrinking fastest (Comirnaty down 20% and Paxlovid down 59% operationally). The 10-K's answer is purchased pipeline rather than defended position: it cites the Seagen and Metsera acquisitions as 'significant investments in obesity and oncology, respectively, which are extremely competitive therapeutic areas', while R&D expense itself fell 4% to $10,437 million. Excluding Comirnaty and Paxlovid the remaining business grew 6% operationally in 2025, which is the honest measure of what is being rebuilt underneath the expiries. A third pressure sits on top of the patent clock and is independent of it: government price-setting now reaches the largest product in the book. |
| Chain position | Upstream photonics supplier into AI/cloud datacenter and telecom infrastructure: sells transceivers, laser chips, CPO components and OCS to cloud operators, AI infrastructure providers and NEMs, and also supplies components to transceiver makers who compete with it ('Some of these competitors are also our customers' — FY2025 10-K). Concentrated demand: Customer A 16.0% and Customer B 15.4% of FY2025 net revenue; manufacturing concentrated in Thailand, China, UK, Slovenia, Japan and US with sole/limited-source component exposure. | Landlord to the AI stack — sells the space, power and interconnection that cloud, network and enterprise tenants run compute in (Oracle, IBM, Meta Platforms, AT&T, Comcast and Lumen are among the customers named in Item 1), with roughly 2.9 GW of total in-place IT capacity. | Demand side of the AI chain, not a supplier into it. The 10-K lists 'Scale AI across our business' as one of four 2026 key priorities and describes 'expanding automation, data-driven decision making, and enterprise AI solutions', crediting 'enhanced digital enablement, including automation and AI' for part of the savings in its cost-realignment and R&D-simplification programs. It describes no AI model, tool or platform that Pfizer sells. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | +0.13 at weight 0.20 · swarm bullish Editorial prior, not backtested. | +0.17 at weight 0.20 · swarm neutral Editorial prior, not backtested. | -0.17 at weight 0.20 · swarm bearish Editorial prior, not backtested. |